---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016452"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:33:02.645989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M

## Summary
- Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.
- Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.
- Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.
- Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.
- MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives.

## SEC filing metadata
- accession: 0001437749-25-016452
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/0001437749-25-016452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/zvra20250106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016452
- JSON: https://secwatch.observer/filing/0001437749-25-016452.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.